{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T16:06:17Z","timestamp":1787069177208,"version":"build-2736575974"},"reference-count":42,"publisher":"Elsevier BV","issue":"12","license":[{"start":{"date-parts":[[2020,12,1]],"date-time":"2020-12-01T00:00:00Z","timestamp":1606780800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"name":"Ferring Pharmaceuticals Inc."}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Urologic Oncology: Seminars and Original Investigations"],"published-print":{"date-parts":[[2020,12]]},"DOI":"10.1016\/j.urolonc.2020.07.004","type":"journal-article","created":{"date-parts":[[2020,9,6]],"date-time":"2020-09-06T08:08:30Z","timestamp":1599379710000},"page":"912-917","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":15,"title":["Update on cardiovascular and metabolic risk profiles of hormonal agents used in managing advanced prostate cancer"],"prefix":"10.1016","volume":"38","author":[{"given":"Celestia S.","family":"Higano","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.urolonc.2020.07.004_bib0001","doi-asserted-by":"crossref","first-page":"1305","DOI":"10.1210\/jc.2005-2507","article-title":"Insulin sensitivity during combined androgen blockade for prostate cancer","volume":"91","author":"Smith","year":"2006","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.urolonc.2020.07.004_bib0002","unstructured":"American Cancer Society. Key statistics for prostate cancer.Https:\/\/www.cancer.org\/cancer\/prostate-cancer\/about\/key-statistics.html. Revised January 8, 2019. Accessed May 17, 2019"},{"key":"10.1016\/j.urolonc.2020.07.004_bib0003","doi-asserted-by":"crossref","first-page":"a2467","DOI":"10.1136\/bmj.a2467","article-title":"Incidence of cardiovascular disease and cancer in advanced age: prospective cohort study","volume":"337","author":"Driver","year":"2008","journal-title":"BMJ"},{"key":"10.1016\/j.urolonc.2020.07.004_bib0004","doi-asserted-by":"crossref","first-page":"3889","DOI":"10.1093\/eurheartj\/ehz766","article-title":"A population-based study of cardiovascular disease mortality risk in US cancer patients","volume":"40","author":"Sturgeon","year":"2019","journal-title":"Eur Heart J"},{"key":"10.1016\/j.urolonc.2020.07.004_bib0005","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1097\/JU.0000000000000714","article-title":"Cardiovascular risk in men with prostate cancer: Insights from the RADICAL PC Study","volume":"203","author":"Leong","year":"2020","journal-title":"J Urol"},{"key":"10.1016\/j.urolonc.2020.07.004_bib0006","unstructured":"Urology Today. Update on ADT in advanced prostate cancer.https:\/\/www.urotoday.com\/journal\/everyday-urology-oncology-insights\/articles\/110209-update-on-adt-in-advanced-prostate-cancer.html. Accessed June 28, 2019"},{"key":"10.1016\/j.urolonc.2020.07.004_bib0007","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1016\/j.hoc.2006.03.013","article-title":"Androgen deprivation therapy: monitoring and managing the complications","volume":"20","author":"Higano","year":"2006","journal-title":"Hematol Oncol Clin N Am"},{"key":"10.1016\/j.urolonc.2020.07.004_bib0008","unstructured":"National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology: prostate cancer version 2.2019.https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/prostate.pdf. Published April 17, 2019. Accessed May 23, 2019."},{"key":"10.1016\/j.urolonc.2020.07.004_bib0009","unstructured":"Thompson IM, Valicenti R, Albertsen PC, et al. Adjuvant and salvage radiotherapy after prostatectomy: ASTRO\/AUA guideline. file:\/\/\/C:\/Users\/Owner\/Downloads\/Radiation-After-Prostatectomy%20(4).pdf. Updated October 2018. Accessed May 20, 2019."},{"key":"10.1016\/j.urolonc.2020.07.004_bib0010","unstructured":"Mottet N, van den Bergh RCN, Briers E, et al. Prostate cancer guidelines 2019. Https:\/\/uroweb.org\/guideline\/prostate-cancer\/. Accessed May 20, 2019."},{"key":"10.1016\/j.urolonc.2020.07.004_bib0011","doi-asserted-by":"crossref","first-page":"1493","DOI":"10.1002\/cncr.22933","article-title":"Androgen deprivation therapy increases cardiovascular morbidity in men with prostate cancer","volume":"110","author":"Saigal","year":"2007","journal-title":"Cancer"},{"key":"10.1016\/j.urolonc.2020.07.004_bib0012","doi-asserted-by":"crossref","first-page":"1516","DOI":"10.1093\/jnci\/djm168","article-title":"Androgen deprivation therapy for localized prostate cancer and the risk of cardiovascular mortality","volume":"99","author":"Tsai","year":"2007","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.urolonc.2020.07.004_bib0013","doi-asserted-by":"crossref","first-page":"3448","DOI":"10.1200\/JCO.2010.29.1567","article-title":"Absolute and relative risk of cardiovascular disease in men with prostate cancer: results from the population-based PCBaSe Sweden","volume":"28","author":"Van Hemelrijck","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.urolonc.2020.07.004_bib0014","doi-asserted-by":"crossref","first-page":"4448","DOI":"10.1200\/JCO.2006.06.2497","article-title":"Diabetes and cardiovascular disease during androgen deprivation therapy for prostate cancer","volume":"24","author":"Keating","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.urolonc.2020.07.004_bib0015","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1016\/j.eururo.2014.11.039","article-title":"Quantifying observational evidence for risk of fatal and nonfatal cardiovascular disease following androgen deprivation therapy for prostate cancer: a meta-analysis","volume":"68","author":"Bosco","year":"2015","journal-title":"Eur Urol"},{"key":"10.1016\/j.urolonc.2020.07.004_bib0016","doi-asserted-by":"crossref","first-page":"2359","DOI":"10.1001\/jama.2011.1745","article-title":"Association of androgen deprivation therapy with cardiovascular death in patients with prostate cancer: a meta-analysis of randomized trials","volume":"306","author":"Nguyen","year":"2011","journal-title":"JAMA"},{"key":"10.1016\/j.urolonc.2020.07.004_bib0017","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.1200\/JCO.2014.59.1792","article-title":"Risk and timing of cardiovascular disease after androgen-deprivation therapy in men with prostate cancer","volume":"33","author":"O'Farrell","year":"2015","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.urolonc.2020.07.004_bib0018","first-page":"1011","article-title":"Treatment and survival of patients with cancer of the prostate","volume":"124","year":"1967","journal-title":"Surg Gynecol Obstet"},{"key":"10.1016\/j.urolonc.2020.07.004_bib0019","doi-asserted-by":"crossref","first-page":"1411","DOI":"10.1016\/j.ijrobp.2011.04.067","article-title":"Influence of androgen deprivation therapy on all-cause mortality in men with high-risk prostate cancer and a history of congestive heart failure or myocardial infarction","volume":"82","author":"Nguyen","year":"2012","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.urolonc.2020.07.004_bib0020","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1016\/S0090-4295(01)01342-5","article-title":"A phase 3, multi-center, open-label, randomized study of abarelix versus leuprolide acetate in men with prostate cancer","volume":"58","author":"McLeod","year":"2001","journal-title":"Urology"},{"key":"10.1016\/j.urolonc.2020.07.004_bib0021","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1016\/j.eururo.2013.10.032","article-title":"Cardiovascular morbidity associated with gonadotropin releasing hormone agonists and an antagonist","volume":"65","author":"Albertsen","year":"2014","journal-title":"Eur Urol"},{"key":"10.1016\/j.urolonc.2020.07.004_bib0022","doi-asserted-by":"crossref","DOI":"10.1097\/JU.0000000000000384","article-title":"Cardiovascular morbidity in a randomized trial comparing GnRH-agonist and GnRH-antagonist among patients with advanced prostate-cancer and pre-existing cardiovascular disease","author":"Margel","year":"2019","journal-title":"J Urol"},{"key":"10.1016\/j.urolonc.2020.07.004_bib0023","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMoa2004325","article-title":"Oral relugolix for androgen-deprivation therapy in advanced prostate cancer","author":"Shore","year":"2020","journal-title":"NEJM"},{"key":"10.1016\/j.urolonc.2020.07.004_bib0024","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1016\/S0022-5347(01)67239-2","article-title":"Effects of the luteinizing hormone-releasing hormone agonist leuprolide on lipoproteins, fibrinogen and plasminogen activator inhibitor in patients with benign prostatic hyperplasia","volume":"154","author":"Eri","year":"1995","journal-title":"J Urol"},{"issue":"8","key":"10.1016\/j.urolonc.2020.07.004_bib0025","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1590\/S1807-59322009000800012","article-title":"Body composition alterations, energy expenditure and fat oxidation in elderly males suffering from prostate cancer, pre and post orchiectomy","volume":"64","author":"Reis","year":"2009","journal-title":"Clinics (Sao Paulo)"},{"key":"10.1016\/j.urolonc.2020.07.004_bib0026","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1016\/j.urology.2003.10.063","article-title":"Changes in fat and lean body mass during androgen-deprivation therapy for prostate cancer","volume":"63","author":"Smith","year":"2004","journal-title":"Urology"},{"key":"10.1016\/j.urolonc.2020.07.004_bib0027","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1210\/jcem.87.2.8299","article-title":"Changes in body composition during androgen deprivation therapy for prostate cancer","volume":"87","author":"Smith","year":"2002","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.urolonc.2020.07.004_bib0028","doi-asserted-by":"crossref","first-page":"2188","DOI":"10.1002\/cncr.23440","article-title":"Metabolic changes during gonadotropin-releasing hormone agonist therapy for prostate cancer: differences from the classic metabolic syndrome","volume":"112","author":"Smith","year":"2008","journal-title":"Cancer"},{"key":"10.1016\/j.urolonc.2020.07.004_bib0029","doi-asserted-by":"crossref","first-page":"1835","DOI":"10.1016\/j.juro.2011.07.035","article-title":"Gonadotrophin-releasing hormone blockers and cardiovascular disease risk","volume":"186","author":"Smith","year":"2011","journal-title":"J Urol"},{"issue":"21","key":"10.1016\/j.urolonc.2020.07.004_bib0030","doi-asserted-by":"crossref","first-page":"3452","DOI":"10.1200\/JCO.2008.20.0923","article-title":"Impact of androgen deprivation therapy on cardiovascular disease and diabetes","volume":"27","author":"Alibhai","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.urolonc.2020.07.004_bib0031","doi-asserted-by":"crossref","unstructured":"Tsai H, Keating NL, Van Den Eeden SK, et al. Risk of diabetes among patients receiving primary androgen deprivation therapy for clinically localized prostate cancer. 2015;193(6):1956-62.","DOI":"10.1016\/j.juro.2014.12.027"},{"key":"10.1016\/j.urolonc.2020.07.004_bib0032","doi-asserted-by":"crossref","unstructured":"Keating NL, Liu PH. O'Malley AJ, Freedland SJ, Smith MR. Androgen-deprivation therapy and diabetes control among diabetic men with prostate cancer. 2014: 65(4):816-824.","DOI":"10.1016\/j.eururo.2013.02.023"},{"issue":"24","key":"10.1016\/j.urolonc.2020.07.004_bib0033","doi-asserted-by":"crossref","first-page":"3979","DOI":"10.1200\/JCO.2006.05.9741","article-title":"Metabolic syndrome in men with prostate cancer undergoing long-term androgen-deprivation therapy","volume":"24","author":"Braga-Basaria","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.urolonc.2020.07.004_bib0034","article-title":"Androgen deprivation therapy and cardiovascular disease","author":"Melloni","year":"2019","journal-title":"Urol Oncol."},{"key":"10.1016\/j.urolonc.2020.07.004_bib0035","doi-asserted-by":"crossref","first-page":"e645","DOI":"10.1016\/j.clgc.2017.12.007","article-title":"The cardiovascular toxicity of abiraterone and enzalutamide in prostate cancer","volume":"16","author":"Iacovelli","year":"2018","journal-title":"Clin Genitourin Cancer"},{"key":"10.1016\/j.urolonc.2020.07.004_bib0036","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1038\/s41391-018-0079-0","article-title":"Androgen-targeted therapy in men with prostate cancer: evolving practice and future considerations","volume":"22","author":"Crawford","year":"2019","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"10.1016\/j.urolonc.2020.07.004_bib0037","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1177\/1758834017698644","article-title":"Abiraterone acetate and prednisone in chemotherapy-na\u00efve prostate cancer patients: rationale, evidence and clinical utility","volume":"9","author":"Crawford","year":"2017","journal-title":"Ther Adv Med Oncol"},{"key":"10.1016\/j.urolonc.2020.07.004_bib0038","series-title":"Prostate Cancer: A Multidisciplinary Approach to Diagnosis and Management","first-page":"337","article-title":"Metastatic castration resistant prostate cancer: role of androgen signaling inhibitors","author":"Poole","year":"2014"},{"key":"10.1016\/j.urolonc.2020.07.004_bib0039","unstructured":"Janssen Ortho LLC: Highlights of prescribing information \u2014 Erleada (apalutamide) tablets.https:\/\/www.janssenlabels.com\/package-insert\/product-monograph\/prescribing-information\/ERLEADA-pi.pdf. Accessed July 2, 2019."},{"key":"10.1016\/j.urolonc.2020.07.004_bib0040","doi-asserted-by":"crossref","first-page":"1408","DOI":"10.1056\/NEJMoa1715546","article-title":"Apalutamide treatment and metastasis-free survival in prostate cancer","volume":"378","author":"Smith","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.urolonc.2020.07.004_bib0041","doi-asserted-by":"crossref","first-page":"1235","DOI":"10.1056\/NEJMoa1815671","article-title":"Darolutamide in nonmetastatic, castration-resistant prostate cancer","volume":"380","author":"Fizazi","year":"2019","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.urolonc.2020.07.004_bib0042","article-title":"Cardiovascular safety of degarelix versus leuprolide for advanced prostate cancer: the PRONOUNCE trial study design","volume":"2","author":"Melloni","year":"2020","journal-title":"JACC Cardio Oncol"}],"container-title":["Urologic Oncology: Seminars and Original Investigations"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1078143920303264?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1078143920303264?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,12,18]],"date-time":"2020-12-18T09:48:08Z","timestamp":1608284888000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1078143920303264"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,12]]},"references-count":42,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["S1078143920303264"],"URL":"https:\/\/doi.org\/10.1016\/j.urolonc.2020.07.004","relation":{},"ISSN":["1078-1439"],"issn-type":[{"value":"1078-1439","type":"print"}],"subject":[],"published":{"date-parts":[[2020,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Update on cardiovascular and metabolic risk profiles of hormonal agents used in managing advanced prostate cancer","name":"articletitle","label":"Article Title"},{"value":"Urologic Oncology: Seminars and Original Investigations","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.urolonc.2020.07.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}